New eye drops aim to soothe dry eyes – first human test underway

NCT ID NCT07640867

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early study tests whether RCI001 eye drops are safe and tolerable in 40 healthy adult men. Participants receive either the active eye drops or a placebo, and researchers monitor for side effects and how the drug behaves in the body. This is a first step toward possibly developing a new treatment for dry eye.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
RCI001 eye drops 0.25%
What this could lead to
If safe and well-tolerated, this could lead to further studies testing RCI001 as a treatment for dry eye symptoms.
What could go wrong
This is a very early Phase 1 trial in only 40 healthy men, not people with dry eye. It only tests safety and how the drug moves through the body, not whether it works for dry eye. Many drugs fail in later stages.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DRY EYE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Seoul national unversity hospital

    Seoul, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.